B+
Bull case
25%
Probability
Target price
$26.00
Analysis reference price unavailable
Analysis 2026-09-24 · RankAlpha Sentiment Codex
CBIO
Crescent BiopharmaCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The July financing provides management-estimated runway into the second half of 2028, while separate CR-001 and CR-003 readouts begin in Q1 2027. Convincing safety and activity could support a substantial re-rating.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -14.0.
What can break
CR-002 trial initiation and 2027 data timing could slip; completion of the earlier IND target is unconfirmed in the supplied evidence.
Momentum
15
Value
41
Sentiment
76
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $15.00 · Bull $26.00 · Bear $7.00Analysis 2026-09-24; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-26 • Vendor: Data Vendor v1
Scores
As of 2026-10-26 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-24 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-26
Investment thesis
As of 2026-10-26
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-26. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $31.50
Why
Momentum15 · Δ7d +5.0
Value41 · Δ7d -0.0
Sentiment76 · Δ7d -14.0
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -14.0.
Contradictions & invalidation
- • CR-002 trial initiation and 2027 data timing could slip; completion of the earlier IND target is unconfirmed in the supplied evidence.
- • China studies rely on Kelun-Biotech execution; collaboration does not remove clinical or regulatory risk.
- • The programs remain clinical-stage, and early data may be inconclusive or disappointing.
Catalyst clock
2026-12-31
CR-002 global trial initiation
Lead driver: Sentiment · See AI snapshot
Momentum
15
8% active weight
Current posture
7d trendImproving
Δ7d
+5.0
Δ21d
-3.2
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.4
Sentiment
76
45% active weight
Current posture
7d trendSoftening
Δ7d
-14.0
Δ21d
+3.2
Why this grade
Composite grade C. Momentum 15.4 / Value 40.6 / Sentiment 76.4
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-24. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$15.00
Analysis reference price unavailable
Analysis 2026-09-24 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$7.00
Analysis reference price unavailable
Analysis 2026-09-24 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-26
Fundamentals (TTM)
As of 2026-10-26
Market Cap
$473.96M
Beta
1.34
Shares Out
37.14M
P/E (TTM) · Derived
-0.9
P/S (TTM)
-
P/FCF (TTM) · Derived
-3.79
Rev YoY
-100.0%
EPS YoY
-85.6%
Gross Margin
+98.2%
Op Margin
-422973.5%
Net Debt
-$211.55M
Current Ratio
9.66
As of 2026-10-26 • Updated nightlySource: Internal modelMethods & Data